Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

NCT03905135 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

Peripheral T-cell Lymphoma NOS
Mycosis Fungoides
Sezary Syndrome
Anaplastic Large Cell Lymphoma

Interventions

DRUG: rhIL-15
DRUG: rhIL-15
BIOLOGICAL: Avelumab

Sponsor

National Cancer Institute (NCI)